Page 158 - product-manual
P. 158

TM/MC  TM/MC
                                          PHARMACOLOGICAL ACTIVITIES - TOXICOLOGY - DRUG INTERACTIONS





                         DRUG     Ulmus rubra
                INTERACTIONS
                                  Validated  interactions  studies  do  not  exist  for  Ulmi  Rubrae  Cortex  preparations.Clinical
                                  interactions with other drugs have not been reported. However, Ulmi Rubrae Cortex extract
                                  may slow the absorption of concomitantly administered oral medications (Brinker, 2001).







            Citrus Bioflavonoids

            Citrus bioflavonoids encompass a diverse set of structures, including rutin, hesperidin, and
            quercetin.  Several  key  studies  have  shown  that  the  anti-inflammatory  properties  of  citrus
            bioflavonoids are due to their inhibition of the synthesis and biological activities of different
            pro-inflammatory mediators, mainly the arachidonic acid derivatives, prostaglandins E , F  and
                                                                                    2  2,
            thromboxane A . The anti-oxidant and anti-inflammatory properties of citrus flavonoids can
                         2
            play a key role in their activity against several degenerative diseases (Benavente & Castillo,
            2008). Ingestion of citric polyphenols in dogs modulates leukocyte functions through changes
            in gene expression (Salas  et al.,  2009).  Studies  have  shown  that  supplementation  of  citrus
            flavanones in obese cats resulted in lower energy intake and decrease in plasma lipids and
            oxidative stress (Jeusette et al., 2010).



                    Toxicity  for  citrus  bioflavonoids  has  not  been  documented  in  dogs  and  cats  when  administered  orally  in
                    therapeutic doses. Oral LD  for quercetin is 160 mg/kg of body weight in mice (IARC, 1999; Merck Index,
                                            50
                    1983). Subcutaneous LD  for quercetin is 100 mg/kg of body weight in mice (IARC, 1999). Intravenous LD
                                                                                                                 50
                                         50
                    for rutin is 950 mg/kg of body weight in mice (Merck Index, 1983). Oral LD  for rutin is 4,750 mg/kg of body
                                                                                     50
                    weight in mice (Patil et al., 2012). In a flavonoid mixture containing 90% diosmin and 10% hesperidin the oral
                TOXICOLOGY  LD  is >3g/kg of body weight in animal studies (Meyer, 1994).
                       50

                    Equivalent toxic dose in 20 kg dog:   3,200 mg PO of quercetin;


                                                    95,000 mg PO of rutin;
                                                    60 g PO of diosmin and hesperidin mixture.
                    Equivalent toxic dose in 5 kg cat:    800 mg PO of quercetin;
                                                    23,750 mg PO of rutin;
                                                    15 g PO of diosmin and hesperidin mixture.


                            DRUG     Validated interactions studies do not exist for citrus bioflavonoid preparations. Clinical
                    INTERACTIONS     interactions with other drugs have not been reported.











                                                                                                  Probenz -VM TM       |  11
   153   154   155   156   157   158   159   160   161   162   163